| Project/Area Number |
16K10707
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory surgery
|
|---|
| Research Institution | Hyogo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
長谷川 誠紀 兵庫医科大学, 医学部, 教授 (10252438)
近藤 展行 兵庫医科大学, 医学部, 講師 (50402889)
多久和 輝尚 兵庫医科大学, 医学部, 非常勤講師 (00412049)
土井 啓至 兵庫医科大学, 医学部, 非常勤講師 (50529047)
|
|---|
| Project Period (FY) |
2016-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 中皮腫 / 癌幹細胞 / Stat3 / 放射線治療 / 悪性胸膜中皮腫 |
|---|
| Outline of Final Research Achievements |
10 μM BBI-608 alone increased ROS in mesothelioma cells than irradiation with 5 Gy or 10 μM Alimta alone. When 10 μM BBI-608 was used in combination with 2 Gy irradiation, ROS production increased more than 2 Gy irradiation or BBI-608 alone. Irradiation (5Gy) increased ROS production more than irradiation (2Gy), but it was not as high as that of BBI-608 single agent (10 μM). When BBI-608 (10 μM) was used in combination with 5 Gy irradiation, the increase in ROS production was equivalent to combination with 2 Gy irradiation.It is considered that the synergistic effect of BBI-608 and radiotherapy is due to this ROS production.
|
| Academic Significance and Societal Importance of the Research Achievements |
Stat 3阻害剤であるBBI-608は癌幹細胞に対する抑制効果が期待されている。本研究はBBI-608と放射線治療の併用時の抗腫瘍効果増大の確認と、そのメカニズムを明らかにすると同時に、動物モデルを用いて同時併用時の安全性が確認出来た。
|
